List of Genetic Analysis/Screening Companies in Germany - 12

ATLAS Biolabs is a leading European service provider of complex analyses in molecular genetics including next-generation sequencing and microarray services supplemented by high-level data analysis. In addition to the high standard and quality, a key benefit of using ATLAS Biolabs’ service portfolio is the close relationship that we build to our customers during project planning and realization. Our quality management is organized according to ISO 9001:2015.

bio.logis is a digital genomics company starting as a spin-off from a genetic diagnostic laboratory setting. Our goal is to develop smart applications and functionalities to drive the implementation of genetic data into clinical decision making. For laboratories and hospitals, we provide highly innovative software solutions enabling automated interpretation, diagnostic reporting & delivery of genetic data. This supports patients and physicians at point of care in making informed decisions based on information derived from DNA. Our vision We want DNA owners to have easy and secure access to reliable health-related information based on their DNA. Our goal is to create a sustainable ecosystem, where all stakeholders contribute to and benefit from maximizing diagnostic quality, improving patient care and promoting research. Our background The bio.logis team consists of experienced human geneticists, scientists and IT experts. Building software solutions for complex medical tasks requires excellent software development expertise and a deep understanding of medical decision making processes. Our team has been formed with exactly this in mind: uniquely combining comprehensive genetic diagnostics knowledge and IT development expertise.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.

Your partner for nucleic acid extraction, biobanking, genotyping, epigenetics, transcriptomics, NGS, proteomics and bioinformatics.

We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.

NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on high quality products made in Germany that enable researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.

At Nostos Genomics, we partner with genetic testing labs to turn data into genomic insights and give more people with genetic diseases a fast and clear diagnosis. Over 300 million people live with a rare genetic disease and for most, the journey from the first symptoms to a diagnosis takes more than 5 years. Even after that, diagnoses are often incorrect, and many people end up not being diagnosed at all. Now, new technology is allowing millions to benefit from genetic testing for diagnosis, while at the same time targeted therapies for previously untreatable disorders are being developed. But the last step in genetic testing – interpreting mutations – remains laborious and costly. It can take a genetic testing lab weeks to interpret data from a single patient. Because of limited understanding of the consequences of mutations, the test results are often inconclusive and leave 70% of people undergoing a genetic test without diagnosis. Our CE-certified platform leverages a unique combination of machine learning and synthetic biology to characterize mutations at scale and automate the interpretation. By offering it to labs, we enable them to diagnose more people in a fraction of the time.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout your project: Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. Technical Expertise: Our team provides unmatched proficiency in your proteomic analysis endeavors. Customized Solutions: We provide customized solutions to meet your specific research needs. Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report. Our Platform Is Used For: • Protein Biomarker Identification and Verification • Novel Drug Target Discovery • Mode-of-Action Analysis • Pathway Activity Analysis • Disease Model Characterization, among other key applications Join us on our mission to revolutionize medicine! #PrecisionMedicine #Proteomics

TIB Molbiol is a medium-sized biotech company based out of Berlin, Germany who has supplied the global market for over 30 years with reagents for research and medical diagnostics. We were recently bought by Roche, one of the largest pharma and biotech companies in the world. Roche has committed to keep the start -up character of the company so that the company can benefit from the advantages of a small biotech and the muscle and power of a large pharma/biotech company such as Roche. Our customers are mainly diagnostic and research labs, servicing patients every day, selecting from any of our more than 2,500 diagnostic kits and LightSNiP assays. We fulfill many special orders for custom design of individual assays, for patient need.